Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
Background The clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between PBRM1 mutations and response with immunotherapy (IO). We sought to determine genomic predictors of differential res...
Saved in:
| Main Authors: | Sumanta Pal, Paulo Gustavo Bergerot, Nazli Dizman, JoAnn Hsu, Yung Lyou, Nicholas Salgia, Daniel Enriquez, Tyler Izatt, Jeffrey M Trent, Sara Byron |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000953.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastasis in renal cell carcinoma: Biology and implications for therapy
by: Jun Gong, et al.
Published: (2016-10-01) -
Renal cell carcinoma: An update for the practicing urologist
by: Sumanta K. Pal, et al.
Published: (2015-01-01) -
Immunotherapy in metastatic prostate cancer
by: Liam Dwyer, et al.
Published: (2025-06-01) -
Gut markers for metastatic melanoma receiving immunotherapy
by: Guoping Ou, et al.
Published: (2025-07-01) -
Chat Reference Service: An Analysis of one Semester's Data.
by: JoAnn Sears
Published: (2001-11-01)